IDOXURIDINE - Generic Drug Details

What are the generic drug sources for idoxuridine and what is the scope of freedom to operate?

Idoxuridine is the generic ingredient in three branded drugs marketed by Glaxosmithkline, Alcon, and Allergan, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for idoxuridine.

Summary for IDOXURIDINE

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	4
Drug Master File Entries:	2
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	1
DailyMed Link:	IDOXURIDINE at DailyMed

Recent Clinical Trials for IDOXURIDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 2
Rush University Medical Center	Phase 2

See all IDOXURIDINE clinical trials

Medical Subject Heading (MeSH) Categories for IDOXURIDINE

Antiviral Agents

Nucleic Acid Synthesis Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for IDOXURIDINE

D06BB	Antivirals
D06B	CHEMOTHERAPEUTICS FOR TOPICAL USE
D06	ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D	Dermatologicals

J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AD	Antivirals
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for IDOXURIDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	STOXIL	idoxuridine	OINTMENT;OPHTHALMIC	015868-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Glaxosmithkline	STOXIL	idoxuridine	SOLUTION/DROPS;OPHTHALMIC	013934-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Alcon	DENDRID	idoxuridine	SOLUTION/DROPS;OPHTHALMIC	014169-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Allergan	HERPLEX	idoxuridine	SOLUTION/DROPS;OPHTHALMIC	013935-002	Approved Prior to Jan 1, 1982		DISCN	No	No

IDOXURIDINE Market Analysis and Financial Projection

Last updated: February 14, 2026

What are the market dynamics for idoxuridine?

Idoxuridine, an antiviral agent approved primarily for topical treatment of herpes simplex virus (HSV) keratitis, has a limited market scope. It is part of the nucleoside analogs class and approved since the 1960s. Its primary market remains ophthalmology, specifically eye infections caused by HSV.

Market Drivers:

• Increased incidence of ocular herpes infections, especially among immunocompromised patients.
• Aging populations leading to higher prevalence of HSV-related keratitis.
• Limited treatment options; alternatives include topical trifluridine and systemic antivirals.

Market Constraints:

• Outdated formulation; newer drugs like trifluridine have replaced it in some regions due to better tolerability.
• Limited manufacturing focus; no recent major improvements or reformulations.
• Regulatory restrictions in certain markets due to toxicity concerns and limited evidence base.

Market Players:

• Original manufacturers included Burroughs Wellcome (now GSK).
• Generic producers hold most of the market share, with limited innovation.

Regional Dynamics:

• High usage in Europe and North America historically.
• Declining prescription trends in developed countries.
• Some growth potential in emerging markets lacking access to newer antivirals.

What is the financial trajectory for idoxuridine?

Financial data on idoxuridine is scarce due to its small, localized market and lack of recent investments.

Revenue estimates:

• Historically, revenue has been modest, estimated under $50 million annually worldwide.
• Market sales declined steadily from the 1990s onward, with some residual use in niche markets.

Pricing:

• Prices vary but generally low, reflecting generic availability.
• Limited patent protection since the 1980s.

Research and development investment:

• Minimal R&D investments in recent decades.
• No ongoing clinical trials or reformulation efforts reported publicly.

Potential for growth:

• High likelihood of market contraction unless new formulations or indications emerge.
• Off-label or research uses are unlikely to generate significant revenue.

How do regulatory policies influence idoxuridine?

• Approved primarily in the 1960s-1970s, with approvals in the U.S., Europe, and Japan.
• Regulatory agencies have not prioritized re-evaluation or reformulation efforts.
• Safety concerns due to mutagenic potential limit broader therapeutic application.
• No recent regulatory filings or approvals for new indications.

How does competitive landscape affect its commercial viability?

• Outcompeted by trifluridine, ganciclovir, and newer topical antivirals.
• No significant patent protections in recent decades.
• Generic manufacturers dominate sales, limiting profitability.

Summary of market and financial outlook

Idoxuridine faces a contracting market with minimal growth prospects. Its older formulation and safety profile restrict its appeal. The dominant trend involves shift toward newer drugs with better tolerability. Small residual demand exists mostly in niche or research settings, with negligible revenue prospects.

Key Takeaways

• Idoxuridine's global sales remain below $50 million annually, declining over decades.
• It is largely replaced by newer antiviral agents in clinical practice.
• No recent R&D or regulatory filings indicate innovation interest.
• Its market is limited to niche applications, mainly in ophthalmology.
• Future growth hinges on reformulation or new indications, which are unlikely without significant investment.

FAQs

1. Could idoxuridine regain ground in the antiviral market?
   Unlikely, given existing safety concerns and competition from more effective, better-tolerated drugs.

2. Are there ongoing clinical trials for idoxuridine?
   No known recent clinical trials or research activities are publicly documented.

3. Is there potential for reformulating idoxuridine?
   Potential exists if safety and efficacy can be improved, but such efforts require substantial investment with uncertain returns.

4. What markets could see renewed interest in idoxuridine?
   Developing countries with limited access to newer therapeutics might use it as a low-cost option, but sales are expected to remain minimal.

5. Can idoxuridine be used off-label for other viral infections?
   While theoretically possible, off-label use is limited by safety concerns and lack of supporting evidence.

---

References

1. "Idoxuridine." Drugs.com, https://www.drugs.com/monograph/idoxuridine.html.
2. "Herpes Simplex Virus Infections." CDC, https://www.cdc.gov/std/herpes/stdfact-herpes.htm.
3. "Antiviral Agents in Ophthalmology." Expert Review of Ophthalmology, 2010.
4. "Market Research for Ophthalmic antivirals." IQVIA, 2022.
5. "Regulatory Status of Nucleoside Analogs." FDA, EMA approvals database.